Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of giredestrant + palbociclib vs letrozole + palbociclib in ER-positive, HER2-negative advanced breast cancer
jRCT2071200038Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of giredestrant in breast cancer (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Progression-Free Survival. Started Oct 2020; status: active, not recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2071200038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200038.